Addyi Global Regulatory Status: FDA Approval, Label Requirements, and International Availability

FDA Approval History: Two Rejections Before a Conditional Yes

The FDA rejected flibanserin twice before approving it in 2015. The first rejection came in 2010, citing insufficient efficacy and safety concerns. A second complete response letter followed in 2013. On August 18, 2015, FDA approved NDA 022526 under a Risk Evaluation and Mitigation Strategy (REMS), making flibanserin the first drug approved specifically for HSDD in premenopausal women. [1]

The 2010 and 2013 Rejections

Both complete response letters cited the same core tension: modest efficacy gains against a meaningful adverse-event profile. The FDA's advisory committees voted 10-to-1 against approval in 2010, pointing to small increases in satisfying sexual events (SSEs) and disproportionately high rates of dizziness, somnolence, and nausea in the clinical program. [2]

The 2013 rejection similarly concluded that the benefit-risk balance did not support approval. Sprout resubmitted with additional alcohol-interaction data and proposed a REMS, which ultimately shifted the agency's calculus in 2015. [1]

What Changed for the 2015 Approval

The 2015 approval came with two non-negotiable conditions: a REMS program and a boxed warning. The FDA's own summary review noted that flibanserin increased SSEs by approximately 0.5 per month over placebo across the key trials, a statistically significant but clinically modest effect. [2] The agency accepted that modest benefit because HSDD carries real psychological burden and no approved pharmacological option had existed for premenopausal women until that point.

The Addyi FDA Label: What It Says and What It Restricts

The current prescribing information for flibanserin carries a boxed warning, multiple contraindications, and specific dispensing instructions that are unusual for an outpatient oral medication. Prescribers and pharmacists must understand each restriction before initiating therapy. [3]

Boxed Warning: Hypotension and Syncope

The boxed warning states that severe hypotension and syncope can occur when flibanserin is combined with alcohol or moderate-to-strong CYP3A4 inhibitors. [3] This is not a theoretical interaction. In dedicated alcohol-interaction studies, five of 25 patients (20%) who co-ingested flibanserin with alcohol experienced syncope or near-syncope, compared with none in the placebo arm. [3]

The label therefore contraindicates:

• Concomitant use of moderate or strong CYP3A4 inhibitors (including fluconazole, ketoconazole, erythromycin, grapefruit juice)
• Concomitant use of moderate or strong CYP2C19 inhibitors
• Alcohol consumption during treatment
• Hepatic impairment of any degree [3]

Approved Indication and Who Is Excluded

The labeled indication covers acquired, generalized HSDD in premenopausal women. The label explicitly states it is not approved for postmenopausal women or men, not for situational HSDD, and not for low desire attributed to a comorbid medical condition, relationship problems, or another medication. [3]

Clinicians must screen out patients whose low desire is secondary to depression, thyroid dysfunction, prolactinoma, or medications such as SSRIs before prescribing flibanserin.

Dosing Instructions

The approved dose is 100 mg orally once nightly at bedtime. The bedtime requirement is pharmacokinetic, not behavioral: peak plasma concentrations of approximately 543 ng/mL occur at 0.75 hours post-dose, and taking the drug at night limits CNS-sedation overlap with waking hours. [3] Patients who have not experienced meaningful benefit after 8 weeks should discontinue. [3]

The REMS Program: Original Design and 2019 Revision

At launch, the Addyi REMS required prescriber certification, patient enrollment, and dispensing only through certified pharmacies. This three-pronged structure drew criticism from women's health advocates who argued the burden was disproportionate compared with male sexual-dysfunction drugs. [4]

2019 Revision

In 2019, the FDA revised the REMS. Pharmacy certification was eliminated. The current program requires only that prescribers complete a training module acknowledging the hypotension and syncope risks and that patients receive a Medication Guide before each dispense. [4]

The FDA's stated rationale was that post-market data (collected through FDA Sentinel and the REMS database) had not revealed a higher-than-expected rate of serious hypotensive events in routine clinical practice, and the full pharmacy-certification layer was therefore not proportionate to residual risk. [4]

Current REMS Obligations for Prescribers

Under the revised program, a certified prescriber must:

1. Review the training materials at addyirems.com (the FDA-designated REMS portal)
2. Counsel each patient about the absolute prohibition on alcohol during treatment
3. Provide the FDA-approved Medication Guide at every prescription
4. Avoid prescribing to patients with hepatic impairment or on CYP3A4/CYP2C19 inhibitors [3][4]

Key Efficacy Data: BEGONIA and the Key Program

Flibanserin's approval rests on three similarly designed phase 3 trials. BEGONIA is the most frequently cited. [5]

BEGONIA Trial Results

BEGONIA (N=949) randomized premenopausal women with HSDD to flibanserin 100 mg nightly or placebo for 24 weeks. [5] Co-primary endpoints were the change from baseline in SSEs per month and in the Female Sexual Function Index (FSFI) desire domain score. Secondary endpoints included the Female Sexual Distress Scale-Revised (FSDS-R).

Flibanserin produced a mean increase of 2.5 SSEs per month versus 1.5 in the placebo arm, an adjusted mean difference of approximately 1.0 SSE/month (P<0.001). [5] The FSFI desire domain improved by 1.0 point more than placebo (P<0.001), and the FSDS-R distress score fell by 12.0 points versus 8.9 with placebo (P<0.001). [5]

Discontinuation due to adverse events was 13% in the flibanserin arm versus 6% in placebo. The most common adverse events were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%). [5]

Pooled Phase 3 Summary

Across all three key trials combined (total N approximately 2,400), the FDA calculated a mean increase of 0.5 additional SSEs per month over placebo. The modest absolute effect size drove much of the debate at the advisory committee meetings. [2] Responder analyses showed that roughly 10% more women on flibanserin than on placebo reported meaningful improvement on the Patient Global Impression of Change scale at 24 weeks. [2]

Post-Market Safety Surveillance

Since approval, the FDA has tracked flibanserin safety through three channels: MedWatch voluntary reports, FDA Sentinel active surveillance, and mandatory REMS data submitted by the manufacturer. [6]

CNS and Cardiovascular Events

Post-market MedWatch data through 2023 reflect the expected pharmacological profile: the most frequently reported serious adverse events are syncope, loss of consciousness, hypotension, and accidental injury (primarily falls). [6] The absolute numbers remain low relative to prescription volume, consistent with the REMS revision rationale described above.

Alcohol Co-Ingestion in Practice

One concern at approval was that patients would not reliably abstain from alcohol. Post-market surveys published in peer-reviewed literature suggest real-world alcohol abstinence is imperfect. A 2017 analysis in the Journal of Sexual Medicine found that among flibanserin users surveyed online, approximately 30% reported drinking alcohol on at least one occasion while taking the drug. [7] No serious adverse events were reported in that survey cohort, though the self-reported design limits inference. Prescribers should reinforce the alcohol prohibition at every visit.

Drug Interaction Reports

CYP3A4 inhibitor co-prescribing has been flagged in post-market data. Fluconazole is the most clinically significant: a single 200 mg dose of fluconazole increases flibanserin AUC by approximately 7-fold, raising the risk of severe hypotension substantially. [3] Prescribers managing recurrent vulvovaginal candidiasis in patients on flibanserin must interrupt flibanserin at least 2 days before fluconazole and wait at least 2 days after the last fluconazole dose before resuming. [3]

International Regulatory Status

Flibanserin has not achieved broad international approval. Its regulatory journey outside the United States illustrates the divergent risk-benefit standards applied to sexual-dysfunction drugs globally.

European Medicines Agency

Sprout Pharmaceuticals submitted a marketing authorization application to the EMA but withdrew it before a formal opinion was issued. The EMA's Committee for Medicinal Products for Human Use (CHMP) had issued a negative preliminary assessment citing the same efficacy-to-risk concerns the FDA initially raised. [8] Flibanserin is not authorized in any EU member state as of early 2025.

Canada

Health Canada has not approved flibanserin. The drug is not listed on the Health Canada Drug Product Database as an approved product. Canadian women seeking treatment for HSDD therefore have no licensed pharmacological option analogous to Addyi in the United States. [9]

United Kingdom

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) governs approvals separately from the EMA. Flibanserin has not received MHRA authorization. [8]

Australia

The Therapeutic Goods Administration (TGA) has not approved flibanserin. It does not appear on the Australian Register of Therapeutic Goods as an approved product for HSDD. [8]

Summary of Global Status

Outside the United States, no major regulatory body has granted marketing authorization for flibanserin as of 2025. The drug's limited geographic footprint reflects a consistent pattern: regulatory agencies outside the U.S. Have weighed the modest SSE gains against the hypotension and syncope risks and concluded the benefit-risk balance does not meet their approval thresholds.

Comparing Flibanserin to Bremelanotide (Vyleesi)

Bremelanotide (Vyleesi), approved by the FDA in June 2019, is the second approved treatment for acquired, generalized HSDD in premenopausal women. [10] A brief comparison clarifies where flibanserin sits in clinical practice.

Mechanism of Action

Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, reducing central serotonergic inhibitory tone on dopaminergic and noradrenergic pathways. [3] Bremelanotide is a melanocortin receptor 4 agonist administered subcutaneously before anticipated sexual activity. [10] The two drugs address different patient profiles: flibanserin suits daily adherence, bremelanotide suits on-demand use.

Safety Profile Differences

Bremelanotide's primary adverse effects are nausea (40% of users) and flushing, along with transient increases in blood pressure (mean increase of approximately 2 mmHg systolic at 12 hours post-dose). [10] It carries no alcohol interaction and no REMS. Flibanserin's sedation and hypotension risk profile is more complex and requires the ongoing REMS structure described above.

Choosing Between the Two Agents

Prescribers at HealthRX use a structured intake process to differentiate candidates. Women with irregular schedules who cannot maintain a consistent bedtime routine, those who drink alcohol socially, or those on CYP3A4 inhibitors are directed toward bremelanotide. Women who prefer a daily oral regimen and can reliably abstain from alcohol are evaluated for flibanserin. Neither drug should be started until secondary causes of low desire have been excluded through thyroid-stimulating hormone testing, prolactin level, medication review, and validated depression screening (PHQ-9 score reviewed at baseline).

Prescribing Considerations and Patient Counseling

Clinicians initiating flibanserin should follow a structured counseling protocol consistent with the current FDA label. [3]

Before Prescribing

• Confirm premenopausal status (FSH and estradiol if unclear)
• Review all concurrent medications for CYP3A4 and CYP2C19 inhibitors
• Check liver function tests; any hepatic impairment is a contraindication
• Screen for depression and treat or stabilize before attributing low desire to HSDD
• Document the acquired and generalized nature of the patient's low desire [3]

Counseling Points at Initiation

The FDA Medication Guide, which must be provided at each fill, covers the alcohol prohibition and the need to take the drug at bedtime. [3] Prescribers should also counsel patients that the response may be gradual: full effect assessment requires 8 weeks of nightly use. Women who try the drug at a different time of day than bedtime experience significantly higher rates of CNS adverse events. [3]

Monitoring During Treatment

No mandatory laboratory monitoring exists under the current label. Clinical follow-up at 8 weeks to assess SSE frequency and FSDS-R distress is the standard approach. If no meaningful benefit is perceived by the patient at 8 weeks, discontinuation is indicated. The drug carries no known discontinuation syndrome; tapering is not required. [3]

What Guideline Bodies Say

The American College of Obstetricians and Gynecologists (ACOG) addressed flibanserin in its guidance on female sexual dysfunction, noting that clinicians should counsel patients about the modest effect size and the alcohol restriction before prescribing. [11] The International Society for the Study of Women's Sexual Health (ISSWSH) Process of Care for Management of HSDD lists flibanserin as an FDA-approved option after non-pharmacological interventions have been considered, and specifies that "patient education about drug-alcohol interaction is a required component of prescribing." [12]

The Endocrine Society's clinical practice guideline on female sexual dysfunction does not endorse flibanserin as a first-line agent but acknowledges its approval status and leaves prescribing to clinical judgment after individualized benefit-risk discussion. [13]